Green Park Pharma closes £2.2M pre-Series A for liquid medication tech
What's the deal? Green Park PharmaDealroom has a profile for this one. Try Dealroom →, a UK company that develops liquid versions of existing tablet medications, has closed a £2.2M pre-series A funding round. The British Business Bank's South West Investment Fund (SWIF), managed by The FSE GroupDealroom has a profile for this one. Try Dealroom →, contributed £500,000 in equity. The deal also includes an option for a further £4.5M in subsequent rounds.
The company's patented technology creates stable, ready-to-use liquid formulations of drugs for the estimated 20–40% of patients globally who struggle to swallow tablets. Its products work at room temperature with a long shelf life.
Why now? Difficulty swallowing tablets affects not just children but adults dealing with stroke, dementia, and some cancers — conditions with growing patient populations. Green Park Pharma says its products improve medication adherence, dosage accuracy, and convenience for the NHS, patients, and caregivers.
The investment will fund an expansion of operations and workforce, with plans to create ten new roles over the next three years as the company scales globally.
What could go wrong? Pharma reformulation is a competitive space, and securing regulatory approvals and licensing across multiple markets takes time and capital. The £2.2M raise is modest for a company with global ambitions — though the £4.5M follow-on option provides a runway extension if milestones are hit.
The signal: Green Park Pharma sits in an increasingly attractive niche — reformulating existing drugs for better delivery rather than pursuing costly new-molecule development, a lower-risk proposition that appeals to early-stage investors wary of traditional pharma timelines. The round also underscores the British Business Bank's strategy of channelling equity finance into regional life-sciences companies at the early growth stage, with the built-in £4.5M follow-on option suggesting confidence that the company's patented technology can clear the regulatory and commercial hurdles needed to scale globally.
Read more: UK Business Angels Association
